ACRV Acrivon Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACRV

Price (delayed)

$1.85

Market cap

$79.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$47.34M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 47
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7
Highlights
Acrivon Therapeutics's debt has decreased by 31% YoY and by 11% QoQ
The EPS has grown by 10% YoY
ACRV's quick ratio is down by 20% YoY but it is up by 17% from the previous quarter
ACRV's equity is down by 40% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.acrivon.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of ACRV

ACRV stock price

How has the Acrivon Therapeutics stock price performed over time
Intraday
7.56%
1 week
9.47%
1 month
-6.57%
1 year
41.22%
YTD
-23.24%
QTD
3.93%

Financial performance

How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.35M
Net income
-$77.27M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 12% year-on-year and by 2.1% since the previous quarter
ACRV's net income is up by 8% year-on-year

Price vs fundamentals

How does ACRV's price correlate with its fundamentals

Growth

What is Acrivon Therapeutics's growth rate over time

Valuation

What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 10% YoY
The P/B is 50% above the last 4 quarters average of 0.5
ACRV's equity is down by 40% YoY and by 15% QoQ

Efficiency

How efficient is Acrivon Therapeutics business performance
The ROIC has plunged by 63% YoY and by 17% from the previous quarter
Acrivon Therapeutics's return on equity has decreased by 44% YoY and by 13% QoQ
The ROA has contracted by 40% YoY and by 12% from the previous quarter

Dividends

What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRV.

Financial health

How did Acrivon Therapeutics financials performed over time
The total assets is down by 39% year-on-year and by 17% since the previous quarter
ACRV's total liabilities is down by 28% since the previous quarter and by 23% year-on-year
Acrivon Therapeutics's debt is 97% lower than its equity
The debt to equity has surged by 50% since the previous quarter and by 50% year-on-year
ACRV's equity is down by 40% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.